• Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs

    3 days ago - By MedPageToday

    Treatment with mobocertinib led to clinically meaningful benefits with a manageable safety profile in patients with previously treated EGFR exon 20 insertion mutation-positive metastatic non-small cell lung cancer...
    Read more ...